Skip to main navigation

DEFLATEHAE.COM
Investors & News
Careers
Contact

Disease Focus
Community Commitment
Scientific Approach
- Our Science
- Pipeline
Scientific Publications
About Pharvaris

Disease Focus
Community Commitment
Scientific Approach
- Our Science
- Pipeline
Scientific Publications
About Pharvaris

DEFLATEHAE.COM
Investors & News
Careers
Contact

Events

Investor Menu

IR Nav

Overview
News & Events
News Releases Events Publications
Financials
SEC Filings Quarterly Results
Stock
Stock Performance Analyst Coverage
Corporate Governance
Governance Documents Leadership Board of Directors Committee Composition
Resources
Investor FAQs Contact Us Email Alerts

Past Events

Jul 10 - Jul 16, 2021

European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2021

Supporting Materials

Poster PHA022121 C006 EAACI2021 399.8 KB

Pharvaris Presents Clinical Data on Oral PHA121 Supporting the Prophylactic Treatment of Hereditary Angioedema at the EAACI Annual Congress 2021 338.2 KB

Jun 29, 2021 1:00 PM CEST

2021 Annual General Meeting of Shareholders

Supporting Materials

Annual Report and auditor's report 2020 1.9 MB

Convening Notice and Agenda (incl. explanatory notes) 185.3 KB

AGM Announcement 53.6 KB

Voting Proxy 154.9 KB

Jun 4, 2021 9:45 AM CEST

12th C1-Inhibitor Deficiency Angioedema Workshop

Supporting Materials

PHVS 2021 C1-INH Workshop Presentation 3.7 MB

Pharvaris Presents Pharmacokinetic and Pharmacodynamic Data for Oral PHA121, Under Development for the Treatment of HAE, at 12th C1 Inhibitor Deficiency and Angioedema Workshop

Feb 26 - Mar 1, 2021

2021 AAAAI Annual Meeting

Supporting Materials

Pharvaris to Present Clinical Data of PHA121 for the Treatment of Hereditary Angioedema at the 2021 AAAAI Annual Meeting

Pharvaris AAAAI 2021 Late Breaker Poster L23 1.4 MB

Pharvaris Presents Pharmacodynamic Activity of Oral PHA121, Under Development for the Treatment of HAE, at the AAAAI Annual Meeting

Pagination

First page
Previous page
…
Page 8
Page 9
Current page 10

Presentations

Source:

EAACI Annual Congress 2026, Istanbul, Turkey

Oral Deucrictibant Immediate-Release Capsule for On-Demand Treatment of Hereditary Angioedema Attacks: End of Progression Results in the Phase 3 RAPIDe-3 Trial

Source:

EAACI Annual Congress 2026, Istanbul, Turkey

A Clinically Validated Kinin Biomarker Assay to Differentiate Bradykinin-Mediated from Mast Cell-Mediated Angioedema

Source:

EAACI Annual Congress 2026, Istanbul, Turkey

Clinical Cardiovascular Safety Assessment of Oral Deucrictibant

Latest Corporate Presentation

©2026 Pharvaris N.V. © All Rights Reserved

Menu

Privacy Policy
Clinical Trial Privacy Notice
Global Privacy Laws
Terms of Use

FOLLOW US